Tiziana Life Sciences (US:TLSA) Globenewswire·2025-10-29 11:00Core Viewpoint - Tiziana Life Sciences is participating in BIO-Europe 2025 to showcase its innovative immunomodulation therapies, particularly its lead candidate, intranasal foralumab, which targets neuroinflammatory and neurodegenerative diseases [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies, specifically through nasal delivery methods [6]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in ongoing studies [6][5]. Product Development - Intranasal foralumab aims to enhance efficacy, safety, and tolerability compared to traditional intravenous methods, targeting conditions such as non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), and early Alzheimer's disease [2][3]. - The company is currently conducting Phase 2 clinical trials for na-SPMS and MSA, with plans to commence Phase 2 studies in early Alzheimer's disease and amyotrophic lateral sclerosis (ALS) [3]. Clinical Results - In an open-label intermediate sized Expanded Access Program, 14 patients with na-SPMS have been dosed with intranasal foralumab, showing either improvement or stability of disease within 6 months for all patients [4]. - A Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial is also underway for patients with na-SPMS [4]. Event Participation - Tiziana's management team, led by CEO Ivor Elrifi, will engage in one-on-one partnering meetings with biopharma executives and investors at BIO-Europe 2025, which is expected to attract over 5,700 delegates from more than 60 countries [2][3].